Areas of Expertise
  • Breast Cancer
  • Lung Cancer
  • Stomach
  • Oesophageal and Duodenal Cancers
  • Colon and Rectal Cancers
  • Gynaecological Cancers
  • Pancreatic
  • Biliary Tract and Liver Cancers
  • Kidney Cancers
  • Bladder Cancer
  • Prostate Cancer
  • Head and Neck Cancers
  • Skin Cancers
  • Tumours of Soft Tissue and Connective Tissue Origin
  • Bone Tumours
  • Neuroendocrine Tumours and Carcinomas

Education

  • Kocaeli University Faculty of Medicine – 2008
  • Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Internal Medicine, 2014 
  • Afyonkarahisar University of Health Sciences, Health Application and Research Centre, Department of Medical Oncology, 2025

Experience

  • Ağrı Eleşkirt Toprakkale Health Centre, 2008–2009 (General Practitioner)
  • Konya Seydişehir State Hospital, 2014–2016 (Specialist in Internal Medicine)
  • Tokat Niksar State Hospital 2017–2021 (Specialist in Internal Medicine)
  • Sivas Numune Hospital 2025–2026 (Specialist in Medical Oncology)

 

Professional Memberships

  • Turkish Society of Medical Oncology (TTOD)
  • European Society for Medical Oncology (ESMO)
  • Eurasian Oncology Society (AVOD)
  • Society of Oncology and Immunotherapy
  • Academic Young Oncologists’ Association (AGO-DER)

Scientific Publications and Activities

1.1. Articles

1.1.a. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q1 class)

1.1.a.2. Culha, Y., Ozdemir, C., Davarci, S.E. et al. Clinical and prognostic effects of microvascular density and FOXP3-positive T cells in breast cancer. Sci Rep 14, 30341 (2024). [SSCI-Q1]

1.1.a.3. Ünlü B, Demir H, Davarci SE, Culha Y, Baykara M. Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study. J Clin Med. 3 February 2026;15(3):1188. doi: 10.3390/jcm15031188. PMID: 41682869; PMCID: PMC12898793. [SSCI-Q1]

1.1.a.4. Yıldız C, Baykara M, Demir H, Cosar R, Yıldız S, Unlu B, Culha Y, Ozaskin D, Kuday &Özkan M, &Özkan FE, &Özdemir Ç. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study. Medicina (Kaunas). 13 March 2026;62(3):538. doi: 10.3390/medicina62030538. PMID: 41901620; PMCID: PMC13028177. [SSCI-Q1]

1.1.b. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q2 and Q3 categories)

1.1.b.1. Culha Y, Davarci SE, Ünlü B, Özaşkin D, Demir H, Baykara M. Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years. Discov Oncol. 22 April 2024;15(1):126. doi: 10.1007/s12672-024-00952-y. PMID: 38649531; PMCID: PMC11035508. [SSCI-Q2] 

1.1.b.2. Keni Begendi N, Duran M and Culha Y (2026) The Prognostic Nutritional Index, but not the NLR or PLR, is associated with survival in multiple myeloma. Front. Oncol. 16:1745422. doi: 10.3389/fonc.2026.1745422. [SSCI-Q2]

1.1.b.3. Culha Y, Ünlü B, Davarcı SE, Güzel HG, Demir H, Öztürk B, Baykara M. Is the risk of brain metastasis and prognosis different in HER2-low breast cancer? Clin Transl Oncol. May 2026;28(5):1624–1636. doi: 10.1007/s12094-025-04106-6. Epub 12 Nov 2025. PMID: 41222828. [SSCI-Q3]

1.1.b.4. Tural D, &Özkan O, Eylemer Mocan E, Kapar C, Yaslikaya S, Tatlı AM, Akdağ G, Demir H, Bilgetekin I, Selcukbiricik F, Köse F, Sarı M, Erdem GU, Sucuoğlu İşleyen Z, Arslan C, Çelik S, Evrensel T, Erman M, Kazaz SN, Öztürk B, &Çelik H, &Özen M, Erel P, Can Şancı P, Ergün Y, Taban H, Kuzu &ÖF, Ulaş Kahya B, Arslan AM, Sakin A, Araz M, Okutur K, Akgül F, Mirili C, Sevinç A, Atalah F, Düzköprü Y, Gülbağcı B, Yaşar S, Kandemir N, Kosku H, Aydın E, Erdem D, Guliyev M, Çulha Y, Şahin B, Gürsoy P, Ürün Y. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access programme. Future Oncol. November 2025;21(27):3499–3505. doi: 10.1080/14796694.2025.2570637. Epub 16 October 2025. PMID: 41103123; PMCID: PMC12622306. [SSCI-Q3]

Scientific Publications and Activities

1.1. Articles

1.1.a. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q1 class)

1.1.a.2. Culha, Y., Ozdemir, C., Davarci, S.E. et al. Clinical and prognostic effects of microvascular density and FOXP3-positive T cells in breast cancer. Sci Rep 14, 30341 (2024). [SSCI-Q1]

1.1.a.3. Ünlü B, Demir H, Davarci SE, Culha Y, Baykara M. Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study. J Clin Med. 3 February 2026;15(3):1188. doi: 10.3390/jcm15031188. PMID: 41682869; PMCID: PMC12898793. [SSCI-Q1]

1.1.a.4. Yıldız C, Baykara M, Demir H, Cosar R, Yıldız S, Unlu B, Culha Y, Ozaskin D, Kuday &Özkan M, &Özkan FE, &Özdemir Ç. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study. Medicina (Kaunas). 13 March 2026;62(3):538. doi: 10.3390/medicina62030538. PMID: 41901620; PMCID: PMC13028177. [SSCI-Q1]

1.1.b. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q2 and Q3 categories)

1.1.b.1. Culha Y, Davarci SE, Ünlü B, Özaşkin D, Demir H, Baykara M. Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years. Discov Oncol. 22 April 2024;15(1):126. doi: 10.1007/s12672-024-00952-y. PMID: 38649531; PMCID: PMC11035508. [SSCI-Q2] 

1.1.b.2. Keni Begendi N, Duran M and Culha Y (2026) The Prognostic Nutritional Index, but not the NLR or PLR, is associated with survival in multiple myeloma. Front. Oncol. 16:1745422. doi: 10.3389/fonc.2026.1745422. [SSCI-Q2]

1.1.b.3. Culha Y, Ünlü B, Davarcı SE, Güzel HG, Demir H, Öztürk B, Baykara M. Is the risk of brain metastasis and prognosis different in HER2-low breast cancer? Clin Transl Oncol. May 2026;28(5):1624–1636. doi: 10.1007/s12094-025-04106-6. Epub 12 Nov 2025. PMID: 41222828. [SSCI-Q3]

1.1.b.4. Tural D, &Özkan O, Eylemer Mocan E, Kapar C, Yaslikaya S, Tatlı AM, Akdağ G, Demir H, Bilgetekin I, Selcukbiricik F, Köse F, Sarı M, Erdem GU, Sucuoğlu İşleyen Z, Arslan C, Çelik S, Evrensel T, Erman M, Kazaz SN, Öztürk B, &Çelik H, &Özen M, Erel P, Can Şancı P, Ergün Y, Taban H, Kuzu &ÖF, Ulaş Kahya B, Arslan AM, Sakin A, Araz M, Okutur K, Akgül F, Mirili C, Sevinç A, Atalah F, Düzköprü Y, Gülbağcı B, Yaşar S, Kandemir N, Kosku H, Aydın E, Erdem D, Guliyev M, Çulha Y, Şahin B, Gürsoy P, Ürün Y. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access programme. Future Oncol. November 2025;21(27):3499–3505. doi: 10.1080/14796694.2025.2570637. Epub 16 October 2025. PMID: 41103123; PMCID: PMC12622306. [SSCI-Q3]

Resume

Education

  • Kocaeli University Faculty of Medicine – 2008
  • Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Internal Medicine, 2014 
  • Afyonkarahisar University of Health Sciences, Health Application and Research Centre, Department of Medical Oncology, 2025

Experience

  • Ağrı Eleşkirt Toprakkale Health Centre, 2008–2009 (General Practitioner)
  • Konya Seydişehir State Hospital, 2014–2016 (Specialist in Internal Medicine)
  • Tokat Niksar State Hospital 2017–2021 (Specialist in Internal Medicine)
  • Sivas Numune Hospital 2025–2026 (Specialist in Medical Oncology)

 

Professional Memberships

  • Turkish Society of Medical Oncology (TTOD)
  • European Society for Medical Oncology (ESMO)
  • Eurasian Oncology Society (AVOD)
  • Society of Oncology and Immunotherapy
  • Academic Young Oncologists’ Association (AGO-DER)

Publications

Scientific Publications and Activities

1.1. Articles

1.1.a. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q1 class)

1.1.a.2. Culha, Y., Ozdemir, C., Davarci, S.E. et al. Clinical and prognostic effects of microvascular density and FOXP3-positive T cells in breast cancer. Sci Rep 14, 30341 (2024). [SSCI-Q1]

1.1.a.3. Ünlü B, Demir H, Davarci SE, Culha Y, Baykara M. Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study. J Clin Med. 3 February 2026;15(3):1188. doi: 10.3390/jcm15031188. PMID: 41682869; PMCID: PMC12898793. [SSCI-Q1]

1.1.a.4. Yıldız C, Baykara M, Demir H, Cosar R, Yıldız S, Unlu B, Culha Y, Ozaskin D, Kuday &Özkan M, &Özkan FE, &Özdemir Ç. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study. Medicina (Kaunas). 13 March 2026;62(3):538. doi: 10.3390/medicina62030538. PMID: 41901620; PMCID: PMC13028177. [SSCI-Q1]

1.1.b. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q2 and Q3 categories)

1.1.b.1. Culha Y, Davarci SE, Ünlü B, Özaşkin D, Demir H, Baykara M. Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years. Discov Oncol. 22 April 2024;15(1):126. doi: 10.1007/s12672-024-00952-y. PMID: 38649531; PMCID: PMC11035508. [SSCI-Q2] 

1.1.b.2. Keni Begendi N, Duran M and Culha Y (2026) The Prognostic Nutritional Index, but not the NLR or PLR, is associated with survival in multiple myeloma. Front. Oncol. 16:1745422. doi: 10.3389/fonc.2026.1745422. [SSCI-Q2]

1.1.b.3. Culha Y, Ünlü B, Davarcı SE, Güzel HG, Demir H, Öztürk B, Baykara M. Is the risk of brain metastasis and prognosis different in HER2-low breast cancer? Clin Transl Oncol. May 2026;28(5):1624–1636. doi: 10.1007/s12094-025-04106-6. Epub 12 Nov 2025. PMID: 41222828. [SSCI-Q3]

1.1.b.4. Tural D, &Özkan O, Eylemer Mocan E, Kapar C, Yaslikaya S, Tatlı AM, Akdağ G, Demir H, Bilgetekin I, Selcukbiricik F, Köse F, Sarı M, Erdem GU, Sucuoğlu İşleyen Z, Arslan C, Çelik S, Evrensel T, Erman M, Kazaz SN, Öztürk B, &Çelik H, &Özen M, Erel P, Can Şancı P, Ergün Y, Taban H, Kuzu &ÖF, Ulaş Kahya B, Arslan AM, Sakin A, Araz M, Okutur K, Akgül F, Mirili C, Sevinç A, Atalah F, Düzköprü Y, Gülbağcı B, Yaşar S, Kandemir N, Kosku H, Aydın E, Erdem D, Guliyev M, Çulha Y, Şahin B, Gürsoy P, Ürün Y. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access programme. Future Oncol. November 2025;21(27):3499–3505. doi: 10.1080/14796694.2025.2570637. Epub 16 October 2025. PMID: 41103123; PMCID: PMC12622306. [SSCI-Q3]

Scientific Publications and Activities

1.1. Articles

1.1.a. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q1 class)

1.1.a.2. Culha, Y., Ozdemir, C., Davarci, S.E. et al. Clinical and prognostic effects of microvascular density and FOXP3-positive T cells in breast cancer. Sci Rep 14, 30341 (2024). [SSCI-Q1]

1.1.a.3. Ünlü B, Demir H, Davarci SE, Culha Y, Baykara M. Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study. J Clin Med. 3 February 2026;15(3):1188. doi: 10.3390/jcm15031188. PMID: 41682869; PMCID: PMC12898793. [SSCI-Q1]

1.1.a.4. Yıldız C, Baykara M, Demir H, Cosar R, Yıldız S, Unlu B, Culha Y, Ozaskin D, Kuday &Özkan M, &Özkan FE, &Özdemir Ç. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study. Medicina (Kaunas). 13 March 2026;62(3):538. doi: 10.3390/medicina62030538. PMID: 41901620; PMCID: PMC13028177. [SSCI-Q1]

1.1.b. Research articles published in journals indexed by SCI, SSCI, SCI Expanded, AHCI, etc. (Q2 and Q3 categories)

1.1.b.1. Culha Y, Davarci SE, Ünlü B, Özaşkin D, Demir H, Baykara M. Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years. Discov Oncol. 22 April 2024;15(1):126. doi: 10.1007/s12672-024-00952-y. PMID: 38649531; PMCID: PMC11035508. [SSCI-Q2] 

1.1.b.2. Keni Begendi N, Duran M and Culha Y (2026) The Prognostic Nutritional Index, but not the NLR or PLR, is associated with survival in multiple myeloma. Front. Oncol. 16:1745422. doi: 10.3389/fonc.2026.1745422. [SSCI-Q2]

1.1.b.3. Culha Y, Ünlü B, Davarcı SE, Güzel HG, Demir H, Öztürk B, Baykara M. Is the risk of brain metastasis and prognosis different in HER2-low breast cancer? Clin Transl Oncol. May 2026;28(5):1624–1636. doi: 10.1007/s12094-025-04106-6. Epub 12 Nov 2025. PMID: 41222828. [SSCI-Q3]

1.1.b.4. Tural D, &Özkan O, Eylemer Mocan E, Kapar C, Yaslikaya S, Tatlı AM, Akdağ G, Demir H, Bilgetekin I, Selcukbiricik F, Köse F, Sarı M, Erdem GU, Sucuoğlu İşleyen Z, Arslan C, Çelik S, Evrensel T, Erman M, Kazaz SN, Öztürk B, &Çelik H, &Özen M, Erel P, Can Şancı P, Ergün Y, Taban H, Kuzu &ÖF, Ulaş Kahya B, Arslan AM, Sakin A, Araz M, Okutur K, Akgül F, Mirili C, Sevinç A, Atalah F, Düzköprü Y, Gülbağcı B, Yaşar S, Kandemir N, Kosku H, Aydın E, Erdem D, Guliyev M, Çulha Y, Şahin B, Gürsoy P, Ürün Y. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access programme. Future Oncol. November 2025;21(27):3499–3505. doi: 10.1080/14796694.2025.2570637. Epub 16 October 2025. PMID: 41103123; PMCID: PMC12622306. [SSCI-Q3]

Quick Appointment
Randevu alabilmek için hastane ve branş seçmeniz gerekmektedir.
Create an Appointment
Calendar

Thank You

We will contact you as soon as possible. We wish you healthy days!